Fed Regist. 1999 Aug 17;64(158):44653-8.
The Food and Drug Administration (FDA) is issuing a final rule establishing that all over-the-counter (OTC) drug products containing colloidal silver ingredients or silver salts for internal or external use are not generally recognized as safe and effective and are misbranded. FDA is issuing this final rule because many OTC drug products containing colloidal silver ingredients or silver salts are being marketed for numerous serious disease conditions and FDA is not aware of any substantial scientific evidence that supports the use of OTC colloidal silver ingredients or silver salts for these disease conditions.
美国食品药品监督管理局（FDA）正在发布一项最终规定，确定所有含有用于内服或外用的胶体银成分或银盐的非处方（OTC）药品通常不被认为是安全有效的，并且属于标签错误。FDA发布这项最终规定是因为许多含有胶体银成分或银盐的非处方药品正在针对多种严重疾病状况进行销售，而FDA并不知晓有任何实质性科学证据支持将非处方胶体银成分或银盐用于这些疾病状况。
